Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Targeting Fatty Acid Binding Proteins in Multiple Myeloma

Oncotarget

September 21, 2023
In a recent editorial, researchers discuss targeting fatty acid binding proteins to fight multiple myeloma. continue reading »

DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma

News

September 20, 2023
PRESS RELEASE: On September 15, 2023, a new editorial was published in Oncotarget, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma.” continue reading »

Real-Time Live Tissue Sensitivity Assay for Pancreatic Adenocarcinoma

News

September 19, 2023
PRESS RELEASE: On September 15, 2023, a new research paper was published in Oncotarget, entitled, “Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma.” continue reading »

Systemic Treatment for Brain Metastasis in HER2-Positive Advanced Breast Cancer

News

September 13, 2023
PRESS RELEASE: On July 7, 2023, a new editorial was published in Oncotarget, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?” continue reading »

Updates: MET Targeted Therapy for EXON 14 Mutations in Lung Cancer

News

September 11, 2023
PRESS RELEASE: On May 26, 2023, a new editorial was published in Oncotarget, entitled, “Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer.” continue reading »